| DC11380 |
Difelikefalin (CR845)
Featured
|
Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2]. |
|
| DC20347 |
Crebinostat
Featured
|
Crebinostat is a novel cognitive enhancer that inhibits class I HDAC/1/2/3 (IC50=0.7/1.0/2.0 nM), class IIb HDAC6 (IC50=9.3 nM) with weaker inhibition of the class I HDAC8 and no significant inhibition of the class IIa HDAC/4/5/7/9; potently induces acetylation of both histone H3 and histone H4 as well as enhanced the expression of the CREB target gene Egr1 in cultured mouse primary neurons; upregulates Bdnf and Grn, and downregulates Mapt (tau) gene expression-genes; brain penetrant. |
|
| DC5159 |
CP-868596 (Crenolanib)
Featured
|
Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB |
|
| DC11642 |
Cridanimod sodium
Featured
|
Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. |
|
| DC22208 |
cRIPGBM |
cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM). |
|
| DC21980 |
Crisdesalazine |
Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro. |
|
| DC22634 |
Crizotinib hydrochloride
Featured
|
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM. |
|
| DC20926 |
Cromoglicic acid |
Cromoglicic acid is a mast cell stabilizer with anti-inflammatory activity that prevents the release of inflammatory chemicals such as histamine, leukotrienes from mast cells. |
|
| DC8997 |
Cromolyn sodium |
Cromolyn sodium is an antiallergic drug. |
|
| DC8963 |
Crotamiton |
Crotamiton is a drug that is used both as a scabicidal (for treating scabies) and as a general antipruritic. It is a prescription lotion based medicine that is applied to the whole body to get rid of the scabies parasite. |
|
| DC23299 |
CS3 |
CS3 is a potent, selective cIAP1 and cIAP2 inhibitor with IC50 of 16 nM and 85 nM respectively, shows no significant activity against XIAP (IC50>34 uM).. |
|
| DC20999 |
CS-3150 (Esaxerenone;XL-550)
Featured
|
CS-3150 (Esaxerenone, XL-550) is a highly potent, selective and orally active non-steroidal mineralocorticoid receptor antagonist with IC50 of 9.4 nM; displays >1,000-fold selectivity over other steroid hormone receptors, glucocorticoid receptor, androgen receptor and progesterone receptor; inhibits aldosterone-induced transcriptional activation of human mineralocorticoid receptor with IC50 of 3.7 nM, shows superior potency to that of spironolactone and eplerenone; suppresses aldosterone-induced decrease in urinary Na(+)/K(+) ratio, inhibits blood pressure elevation induced by DOCA/salt-loading in rats. |
|
| DC20651 |
CS-526 |
CS-526 (AKU 517. |
|
| DC20089 |
CSF1R-IN-1
Featured
|
CSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM, displays 120-fold selectivity over c-Kit; has improved metabolic stability and Caco2 permeability. |
|
| DC20348 |
CSIC E379 |
CSIC E379 is a potent, selective uncoupling proteins UCP1/UCP2 inhibitor with EC50 of 20 uM/30 uM, respectively. |
|
| DC22209 |
CSLP37
Featured
|
CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC22210 |
CSLP43 |
CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC20930 |
CSN5i-3 |
CSN5i-3 (CSN5 inhibitor 3) is a potent, selective and orally available inhibitor of CSN5 with IC50 of 5.8 nM, the proteolytic subunit of COP9 signalosome (CSN). |
|
| DC12576 |
CSRM617
Featured
|
CSRM617 (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly. |
|
| DC22063 |
CSRM617 hydrochloride |
CSRM617 hydrochloride (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly. |
|
| DC12661 |
CT1812
Featured
|
CT 1812 is a proprietary first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta oligomer receptor antagonist |
|
| DC20932 |
Conteltinib |
CT-707 (Conteltinib) is a novel multikinase inhibitor targeting FAK (IC50=1.6 nM), ALK and Pyk2, exerts synergistic antitumor effects against hepatocellular carcinoma in vitro and in vivo. |
|
| DC22064 |
CTA056 |
CTA056 (CTA 056) is a potent, selective inhibitor of interleukin-2-inducible T-cell kinase (Itk) with IC50 of ~100 nM, also inhibits Btk (IC50=400 nM), but shows no significant inhibition for Etk (BMX kinase, IC50=5 uM). |
|
| DC22065 |
CTA095 |
CTA095 (CTA-095) is a potent Etk (BMX) and Src dual inhibitor with IC50 of 60 and 120 nM, respectively, shows no significant inhibition on Btk and Yes at 10 uM. |
|
| DC11110 |
CTDP-32476 |
CTDP-32476 is a potent and selective dopamine transporter (DAT) inhibitor and a competitive inhibitor of cocaine binding to the DAT with Ki of 12 nM. |
|
| DC7110 |
CTEP
Featured
|
CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM. |
|
| DC22066 |
CTN06 |
CTN06 is a potent Etk (BMX) and Btk dual inhibitor with IC50 of 200 and 50 nM, respectively. |
|
| DC23400 |
CTPB |
CTPB is an anacardic acid derivative, was reported as a selective activator of p300 (KAT3B) HAT activity but not PCAF (KAT2B), which enhanced HAT-dependent transcriptional activation. |
|
| DC11217 |
SLC25A1 inhibitor CTPI-2
Featured
|
CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and |
|
| DC9510 |
CTS-1027 |
CTS-1027 is a potent small molecule inhibitor of MMPs(IC50=0.4 nM/0.6 nM for MMP2/MMP13); >1,000 fold selectivity over MMP1.
|
|
